Featuring perspectives from Dr Lecia Sequist, including the following topics:

Introduction: Journal Club with Lecia V Sequist, MD, MPH (0:00)
Case: A woman in her early 70s with Stage IIB adenocarcinoma of the lung and an EGFR exon 19 mutation— Adam R Miller, MD (19:26)
Case: A man in his late 70s with metastatic adenocarcinoma of the lung and an EGFR L858R mutation develops hemoptysis from an "escape lesion" on osimertinib — Priya Rudolph, MD, PhD (24:59)
Case: A man in his early 70s with metastatic adenocarcinoma of the lung (PD-L1 high) and an EGFR L858R mutation experiences disease progression on pembrolizumab — Sandip Patel, MD (28:45)
Case: A woman in her mid 60s with metastatic adenocarcinoma of the lung with an EGFR exon 20 insertion with multiple brain and bone metastases (PD-L1
Case: A woman in her mid 50s with metastatic adenocarcinoma of the lung and an EGFR mutation experiences disease progression after response to osimertinib x 3 years (PD-L1 TPS 80%) — Gigi Chen, MD (43:44)
Case: A man in his mid 50s with adenocarcinoma of the lung and an EGFR exon 19 mutation with brain metastases and disease progression on both osimertinib and carboplatin/paclitaxel/pembrolizumab/bevacizumab (ROS fusion detected on RNA assay) — Namrata I Peswani, MD (59:12)

Non-Small Cell Lung Cancer | Meet The Professor: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation — Part 2